Anal Cancer - Pipeline Review, H2 2020

August 2020 | 589 pages | ID: A0BDFD902DEEN
Global Markets Direct

Abstracts

Anal Cancer - Pipeline Review, H2 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anal Cancer - Pipeline Review, H2 2020, provides an overview of the Anal Cancer (Oncology) pipeline landscape.

Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness in the anal area. Predisposing factors include HPV infections, smoking and lowered immunity.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anal Cancer - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Anal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 19, 18, 2 and 5 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Anal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Anal Cancer (Oncology).
• The pipeline guide reviews pipeline therapeutics for Anal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Anal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Anal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Anal Cancer (Oncology)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Anal Cancer (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Anal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Anal Cancer - Overview
Anal Cancer - Therapeutics Development
Anal Cancer - Therapeutics Assessment
Anal Cancer - Companies Involved in Therapeutics Development
Anal Cancer - Drug Profiles
Anal Cancer - Dormant Projects
Anal Cancer - Discontinued Products
Anal Cancer - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Anal Cancer, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020 (Contd..2), H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Target, H2 2020 (Contd..1), H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020 (Contd..1), H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Anal Cancer - Pipeline by Antiva Biosciences Inc, H2 2020
Anal Cancer - Pipeline by AstraZeneca Plc, H2 2020
Anal Cancer - Pipeline by Bayer AG, H2 2020
Anal Cancer - Dormant Projects, H2 2020
Anal Cancer - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Anal Cancer, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

COMPANIES MENTIONED

Antiva Biosciences Inc
AstraZeneca Plc
Bayer AG
Beijing Kangle Guardian Biotechnology Co Ltd
Biocon Ltd
Biomimetix JV LLC
BNOAT Oncology Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Cleveland BioLabs Inc
Cue Biopharma Inc
CytomX Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
Fujifilm Holdings Corp
Gilead Sciences Inc
Hookipa Pharma Inc
IMV Inc
Incyte Corp
Invectys SA
ISA Pharmaceuticals BV
Merck & Co Inc
Merck KGaA
Mereo Biopharma Group Plc
Molecular Partners AG
Onconova Therapeutics Inc
Ono Pharmaceutical Co Ltd
PDS Biotechnology Corp
Privo Technologies Inc
Shanghai Zerun Biotechnology Co Ltd
Sotio AS
SQZ Biotechnologies Co
THEVAX Genetics Vaccine USA Inc
Transgene SA
Treadwell Therapeutics Inc
Turnstone Biologics Inc
Virion Therapeutics LLC
Xencor Inc